TY - JOUR
T1 - Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues
AU - Cornaglia, G
AU - Akova, M
AU - Amicosante, G
AU - Cantón, R
AU - Cauda, Roberto
AU - Docquier, J
AU - Edelstein, M
AU - Frère, J
AU - Fuzi, M
AU - Galleni, M
AU - Giamarellou, H
AU - Gniadkowski, M
AU - Koncan, R
AU - Libisch, B
AU - Luzzaro, F
AU - Miriagou, V
AU - Navarro, F
AU - Nordmann, P
AU - Pagani, Laura
AU - Peixe, L
AU - Poirel, L
AU - Souli, M
AU - Tacconelli, Evelina
AU - Vatopoulos, A
AU - Rossolini, Gm
PY - 2007
Y1 - 2007
N2 - The rapid spread of acquired metallo-beta-lactamases (MBLs) among major Gram-negative pathogens is a matter of particular concern worldwide and primarily in Europe, one of first continents where the emergence of acquired MBLs has been reported and possibly the geographical area where the increasing diversity of these enzymes and the number of bacterial species affected are most impressive. This spread has not been paralleled by accuracy/standardisation of detection methods, completeness of epidemiological knowledge or a clear understanding of what MBL production entails in terms of clinical impact, hospital infection control and antimicrobial chemotherapy. A number of European experts in the field met to review the current knowledge on this phenomenon, to point out open issues and to reinforce and relate to one another the existing activities set forth by research institutes, scientific societies and European Union-driven networks.
AB - The rapid spread of acquired metallo-beta-lactamases (MBLs) among major Gram-negative pathogens is a matter of particular concern worldwide and primarily in Europe, one of first continents where the emergence of acquired MBLs has been reported and possibly the geographical area where the increasing diversity of these enzymes and the number of bacterial species affected are most impressive. This spread has not been paralleled by accuracy/standardisation of detection methods, completeness of epidemiological knowledge or a clear understanding of what MBL production entails in terms of clinical impact, hospital infection control and antimicrobial chemotherapy. A number of European experts in the field met to review the current knowledge on this phenomenon, to point out open issues and to reinforce and relate to one another the existing activities set forth by research institutes, scientific societies and European Union-driven networks.
KW - Anti-Bacterial Agents
KW - Drug Resistance, Multiple, Bacterial
KW - European Union
KW - Gram-Negative Bacteria
KW - Gram-Negative Bacterial Infections
KW - Humans
KW - Microbial Sensitivity Tests
KW - beta-Lactam Resistance
KW - beta-Lactamases
KW - Anti-Bacterial Agents
KW - Drug Resistance, Multiple, Bacterial
KW - European Union
KW - Gram-Negative Bacteria
KW - Gram-Negative Bacterial Infections
KW - Humans
KW - Microbial Sensitivity Tests
KW - beta-Lactam Resistance
KW - beta-Lactamases
UR - http://hdl.handle.net/10807/7002
U2 - 10.1016/j.ijantimicag.2006.10.008
DO - 10.1016/j.ijantimicag.2006.10.008
M3 - Article
SN - 0924-8579
VL - 29
SP - 380
EP - 388
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
ER -